Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phenolphthalein carcinogenicity potential to be revisited at April 30 "feedback" meeting.

This article was originally published in The Tan Sheet

Executive Summary

PHENOLPHTHALEIN CARCINOGENICITY POTENTIAL TO BE REVISITED at an FDA OTC "feedback" meeting scheduled for April 30. The meeting will include reconsideration of the OTC laxative ingredient's safety by FDA's Carcinogenicity Assessment Committee, the agency's cancer study review board. The National Toxicology Program will present new transgenic animal data on phenolphthalein at the meeting, which the committee hopes will allow it to make a final determination about the substance's safety.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086944

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel